0000950159-20-000161.txt : 20200730 0000950159-20-000161.hdr.sgml : 20200730 20200730061855 ACCESSION NUMBER: 0000950159-20-000161 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200730 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200730 DATE AS OF CHANGE: 20200730 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cigna Corp CENTRAL INDEX KEY: 0001739940 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 824991898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38769 FILM NUMBER: 201059033 BUSINESS ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 BUSINESS PHONE: 8602266000 MAIL ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 FORMER COMPANY: FORMER CONFORMED NAME: Halfmoon Parent, Inc. DATE OF NAME CHANGE: 20180508 8-K 1 cigna8k.htm CIGNA CORPORATION FORM 8K
0001739940 false 0001739940 2020-07-30 2020-07-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 30, 2020

Cigna Corporation

(Exact name of registrant as specified in its charter)

 

Delaware
(State or other jurisdiction of incorporation)
001-38769
(Commission File Number)
82-4991898
(IRS Employer
Identification No.)

900 Cottage Grove Road

Bloomfield, Connecticut 06002

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code:

(860)226-6000

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, Par Value $0.01 CI New York Stock Exchange, Inc.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 2.02Results of Operations and Financial Condition.

 

On July 30, 2020, Cigna Corporation issued a press release announcing results for the second quarter ended June 30, 2020. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this Current Report on Form 8-K, except as shall be expressly set forth by specific reference in such a filing.

 

 

Item 9.01Financial Statements and Exhibits.

 

(d)Exhibits.

 

Exhibit No. Description

 

99.1Press release dated July 30, 2020.

 

104Cover Page Interactive Data File (embedded within the Inline XBRL).

 

 
 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Cigna Corporation

Date:  July 30, 2020 By:   /s/ Eric P. Palmer
    Eric P. Palmer
    Executive Vice President and Chief Financial Officer
     
     

 

EX-99.1 2 ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Press Release

 

INVESTOR RELATIONS CONTACT:

Will McDowell

215-761-4198

william.mcdowell2@cigna.com

 

MEDIA CONTACT:

Ellie Polack

860-902-4906

elinor.polack@cigna.com

 

 

 

Cigna Expands Stakeholder and Community Support, Reports Second Quarter 2020 Performance

 

Total revenues in the second quarter were $39.3 billion. Adjusted revenues1 were $39.2 billion.
Shareholders’ net income for second quarter was $1.8 billion, or $4.73 per share
Adjusted income from operations2 for the second quarter was $2.2 billion, or $5.81 per share
Adjusted income from operations2,3 is projected to be in the range of $18.00 to $18.60 per share in 20203

 

BLOOMFIELD, CT, July 30, 2020 – Global health service company Cigna Corporation (NYSE: CI) continues to expand stakeholder and community support and today reported second quarter 2020 performance.

 

“Cigna's mission to improve the health, well-being and peace of mind of those we serve continues to guide us as we remain relentlessly focused on supporting the needs of our customers, clients, and communities,” said David M. Cordani, President and Chief Executive Officer. “Our stakeholders are facing unprecedented challenges from the pandemic, uncertainty of a disrupted economy, and pain of racial tensions and inequality. We are proud of the actions we have taken to provide innovative programs and services and expanded financial support, all while delivering sustained, attractive financial performance and generating substantial cash flows that fuel our offerings for the benefit of all we serve.”

 

Total revenues for second quarter 2020 were $39.3 billion. Adjusted revenues1 were $39.2 billion and reflect strong contributions from each of Cigna's ongoing businesses.

 

Shareholders’ net income for second quarter 2020 was $1.8 billion, or $4.73 per share, compared with $1.4 billion, or $3.70 per share, for second quarter 2019.

 

Cigna's adjusted income from operations2 for second quarter 2020 was $2.2 billion, or $5.81 per share, compared with $1.6 billion, or $4.30 per share, for second quarter 2019 reflecting the impact of deferred medical utilization due to the COVID-19 pandemic as well as ongoing focused execution across our businesses.

 

Reconciliations of total revenues to adjusted revenues1 and of shareholders’ net income to adjusted income from operations2 are provided on the following page, and on Exhibit 1 of this earnings release.

 

 
2 

 

CONSOLIDATED HIGHLIGHTS

 

The following table includes highlights of results and reconciliations of total revenues to adjusted revenues1 and shareholders’ net income to adjusted income from operations2:

 

Consolidated Financial Results (dollars in millions):

 

   Three Months Ended  Six Months Ended
June 30,  March 31,  June 30,
   2020  2019  2020  2020
Total Revenues  $39,265   $38,819   $38,469   $77,734 
Net Realized Investment (Gains) Losses from Equity Method Investments1   (60)   6    10    (50)
Special Items1   —      —      (87)   (87)
Transitioning Client Contributions1   —      (4,450)   —      —   
Adjusted Revenues1  $39,205   $34,375   $38,392   $77,597 
                     
Consolidated Earnings, net of taxes                    
Shareholders’ Net Income  $1,754   $1,408   $1,181   $2,935 
Net Realized Investment (Gains) Losses2   (88)   (13)   77    (11)
Amortization of Other Acquired Intangible Assets2   376    572    309    685 
Special Items2   110    179    191    301 
Transitioning Client Contributions1,2   —      (506)   —      —   
Adjusted Income from Operations2  $2,152   $1,640   $1,758   $3,910 
                     
Shareholders’ Net Income, per share   $4.73   $3.70   $3.15   $7.88 
Adjusted Income from Operations2, per share  $5.81   $4.30   $4.69   $10.49 

 

Cigna’s second quarter results reflect revenue and earnings growth due to strong fundamental performance and lower medical costs from deferred care related to the COVID-19 pandemic.

 

Year to date through July 29, 2020, the Company repurchased 8.3 million shares of common stock for approximately $1.5 billion.

 

The debt to capitalization ratio decreased to 43.5% at June 30, 2020 from 45.2% at December 31, 2019.

 

The SG&A expense ratio4 was 8.4% for second quarter 2020, a decrease from 9.0% for second quarter 2019, driven by significant revenue growth and continued expense efficiency.

 

 
3 

 

CUSTOMER RELATIONSHIPS

 

The following table summarizes Cigna’s medical customers and overall customer relationships:

 

Customer Relationships (in thousands):

 

   As of the Periods Ended   
   June 30,  March 31,  December 31,
   2020  2019  2020  2019
             
Total Pharmacy Customers5   84,919    75,171    78,804    75,903 
                     
Commercial   14,000    14,026    14,140    14,187 
Government   1,415    1,382    1,412    1,361 
International Markets   1,668    1,589    1,666    1,597 
Total Medical Customers5   17,083    16,997    17,218    17,145 
                     
Behavioral Care   37,061    28,577    37,231    30,361 
Dental   17,850    17,077    18,018    17,231 
Medicare Part D   3,300    3,266    3,295    3,276 
International Markets Supplemental Policies5,6   12,098    12,500    12,453    12,444 
Group Disability and Life Covered Lives5   15,900    15,400    15,900    15,400 
Total Customer Relationships   188,211    168,988    182,919    171,760 
                     

 

The pharmacy customer base5 at second quarter 2020 grew to 84.9 million, an organic increase of 9.0 million customers year to date, driven by strong new health plan sales.

 

The total medical customer base5 at second quarter 2020 was 17.1 million, a decrease of 62,000 customers year to date, driven by a decline in National Accounts, partially offset by growth in Medicare Advantage and the Select and International Markets segments.

 

 

 

 
4 

 

HIGHLIGHTS OF SEGMENT RESULTS

 

See Exhibit 1 for a reconciliation of adjusted income (loss) from operations2 to shareholders’ net income.

 

 

Health Services

 

This segment includes a broad range of services, including benefits management, specialty pharmacy services, clinical solutions, home delivery, and health management services.

 

Financial Results (dollars in millions):        

 

  Three Months Ended  Six Months Ended
  June 30,  March 31,  June 30,
   2020  2019  2020  2020
Adjusted Revenues1   $28,602   $23,537   $27,168   $55,770 
Adjusted Income from Operations, Pre-Tax2   $1,249   $1,162   $1,082   $2,331 
Adjusted Margin, Pre-Tax7   4.4%   4.9%   4.0%   4.2%

 

Second quarter 2020 adjusted revenues1 increased 22% relative to second quarter 2019 driven by the insourcing of Integrated Medical pharmacy volumes and strong organic growth, including continued growth in specialty pharmacy services, partially offset by reduced retail script volumes due to the COVID-19 pandemic.

 

Second quarter adjusted income from operations, pre-tax2 increased 7% relative to second quarter 2019, reflecting customer growth, higher adjusted pharmacy scripts volumes, benefits from the effective management of the supply chain, and continued strong performance in specialty pharmacy services, partially offset by an increase in operating expenses to support growth.

 

Health Services fulfilled 364 million adjusted pharmacy scripts8 in second quarter 2020, an increase of 24% over second quarter 2019 driven by the insourcing of Integrated Medical pharmacy volumes and strong organic growth, partially offset by reduced retail script volumes.

 

 

 
5 

 

Integrated Medical

 

This segment includes Cigna’s U.S. Commercial and Government businesses that provide comprehensive medical solutions to clients and customers. U.S. Commercial products and services include medical, pharmacy, behavioral health, dental, vision, health advocacy programs and other products and services to insured and self-insured customers. Government solutions include Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, Medicaid plans, and individual health insurance coverage both on and off the public exchanges.

 

Financial Results (dollars in millions):

  Three Months Ended  Six Months Ended
  June 30,  March 31,  June 30,
   2020  2019  2020  2020
Adjusted Revenues1  $9,237   $8,968   $9,860   $19,097 
Adjusted Income from Operations, Pre-Tax2  $1,523   $990   $1,199   $2,722 
Adjusted Margin, Pre-Tax7   16.5%   11.0%   12.2%   14.3%

 

 

Second quarter 2020 adjusted revenues1 grew 3% over second quarter 2019, reflecting customer growth in Medicare Advantage and in the Select segment, as well as premium increases, partially offset by premium relief programs for clients that were delivered in response to the COVID-19 pandemic. The sequential decline in adjusted revenues1 was primarily due to premium relief programs for clients, lower net investment income, and a modest decline in medical customers.

 

Second quarter 2020 adjusted income from operations, pre-tax² and adjusted margin, pre-tax7 reflect significantly lower medical utilization in both the Commercial and Government segments compared to historic patterns, as individuals deferred care due to the COVID-19 pandemic, partially offset by premium relief programs for clients and cost share waivers for customers.

 

The medical care ratio4 (“MCR”) of 70.5% for second quarter 2020 reflects significantly lower medical utilization in both the Commercial and Government segments compared to historic patterns, as individuals deferred care due to the COVID-19 pandemic, partially offset by premium relief programs for clients and cost share waivers for customers.

 

Integrated Medical net medical costs payable9 was $2.80 billion at June 30, 2020, $2.64 billion at June 30, 2019, and $2.59 billion at December 31, 2019. Year to date, favorable prior year reserve development on a gross pre-tax basis was $130 million and $149 million through second quarter 2020 and 2019, respectively.

 

 

 
6 

 

International Markets

 

This segment includes supplemental health, life and accident insurance products and health care coverage in Cigna’s international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations.

 

Financial Results (dollars in millions):

 

  Three Months Ended  Six Months Ended
  June 30,  March 31,  June 30,
   2020  2019  2020  2020
Adjusted Revenues1,6  $1,432   $1,389   $1,470   $2,902 
Adjusted Income from Operations, Pre-Tax2  $319   $207   $282   $601 
Adjusted Margin, Pre-Tax7   22.3%   14.9%   19.2%   20.7%

 

 

Second quarter 2020 adjusted revenues1,6 grew 3% over second quarter 2019, reflecting continued business growth, partially offset by adverse foreign currency movement.

 

Second quarter 2020 adjusted income from operations, pre-tax2 and adjusted margin, pre-tax7 reflect lower claim levels driven by the COVID-19 pandemic, continued business growth and operational efficiency.

 

 
7 

 

Group Disability and Other Operations

 

This segment includes Cigna’s Group Disability and Life business which offers group long-term and short-term disability, and group life, accident, voluntary and specialty insurance products and services. Additionally, this segment includes Corporate Owned Life Insurance (“COLI”) and the Company’s run-off operations.

 

Financial Results (dollars in millions):

 

  Three Months Ended  Six Months Ended
  June 30,  March 31,  June 30,
   2020  2019  2020  2020
Adjusted Revenues1  $1,328   $1,309   $1,339   $2,667 
Adjusted Income from Operations, Pre-Tax2   $132   $149   $77   $209 
Adjusted Margin, Pre-Tax7   9.9%   11.4%   5.8%   7.8%

 

 

Second quarter 2020 adjusted income from operations, pre-tax2 and adjusted margin, pre-tax7 reflect elevated claims in Cigna’s Life business primarily related to the COVID-19 pandemic, partially offset by favorable performance within the Disability business.

 

On December 18, 2019, Cigna announced a definitive agreement whereby New York Life will acquire Cigna's Group Disability and Life business for $6.3 billion. Cigna expects the transaction to close in the third quarter of 2020, subject to applicable regulatory approvals and other customary closing conditions.

 

 

 

Corporate

 

Corporate reflects interest expense, as well as amounts not allocated to operating segments and includes intersegment eliminations.

 

Financial Results (dollars in millions):
         

 

  Three Months Ended  Six Months Ended
  June 30,  March 31,  June 30,
   2020  2019  2020  2020
Adjusted (Loss) from Operations, Pre-Tax2  $(400)  $(453)  $(405)  $(805)

 

Second quarter 2020 adjusted loss from operations, pre-tax2 decreased relative to second quarter 2019 as a result of lower interest expense.

 

 

 
8 

  

COVID-19 Response

 

From the onset of the COVID-19 pandemic, Cigna has focused on delivering peace of mind for the people and businesses we serve, and our employees and their families. We’ve taken bold actions to drive affordability, remove uncertainty, and make health care easier. To date, these actions include:

 

 

Making Health Care Affordable

Waived customer out-of-pocket costs for COVID-19 related visits, testing and treatment delivered by any in-network provider anywhere – whether at an office, an urgent care center, emergency room or through virtual care.10
Protecting customers from surprise bills by out-of-network providers through the Customer Protection Program.
Customers can utilize free standard shipping for home delivery of maintenance medications.
Helping people temporarily without coverage access prescription savings through Parachute Rx.
Employers can provide tax-free financial assistance to employees for qualified disaster relief payments, such as medical payments, groceries, child care, and wellness services with the Cigna Care Card.
Expanding financial assistance to Cigna group dental clients by issuing one-month premium credits.
Offering financial relief to clients through its Guaranteed Cost Client Relief Program.

 

Making Health Care Predictable

Helping customers get COVID-19 care in the safety of their home from Medocity.
Protecting prescription medication supply through quantity limits as needed.
24/7 customer access to pharmacists.
Waived prior authorizations for patient transfers, emergency department visits and home health care services.
Customers can utilize virtual care for non-COVID-19 issues at the standard in-office benefit.
Acute and advanced illness care offered at home.

 

Making Health Care Simple

Encouraged use of virtual care, and have seen 132K+ visits through telehealth partners MDLIVE and Amwell.
Cigna Dental customers can utilize Cigna Dental Virtual Care powered by The TeleDentists.
Buoy Health (U.S.) and Infermedica (international) tools provide COVID-19 symptom checkers. To date, 100K+ customers have used Buoy.

Digital mental health care tools available include Happify, iPrevail and Talkspace, and SilverCloud Health.
Expanded Employee Assistance Programs for customers and households, and have seen a significant increase in consultations.

 

Supporting Communities

Cigna and the Cigna Foundation11 launched the Brave of Heart Fund with a $25M grant to provide financial assistance to survivors of frontline U.S. workers who gave their lives in COVID-19 fight. The Fund was created in partnership with the New York Life Foundation. Cigna will also provide emotional support services at no cost.
Providing free on-demand supportive resources for customers and the general public, such as online articles, podcasts, and webinars.
24/7 free mental health support line for the public.
Cigna has not requested or retained any proceeds under the CARES Act.

 

Supporting Our Workforce

In less than one month’s time, enabled nearly 100% of employees who could work from home to do so, globally.
Lifted restriction on paid time off use before accrual.
Employees have 10 paid Emergency Time Off days for COVID-19 related absences.
20% pay premium for U.S. worksite-essential employees.
Enhanced employee recognition program.
Introduced the Cigna COVID-19 Employee Assistance Fund to help offset extraordinary financial hardships.
Launched Employees Helping Employees: Cloth Face Coverings campaign for employees to make masks for worksite essential coworkers.
Ensuring workplace health through enhanced safety protocols, including PPE for frontline staff.
 
9 

 

2020 OUTLOOK

 

Cigna's outlook for full year 2020 adjusted revenues1,3 is $154 billion to $156 billion. Cigna’s outlook for full year 2020 consolidated adjusted income from operations2,3 on a per share basis is in the range of $18.00 to $18.60 per share. Cigna’s outlook excludes potential effects of any future share repurchase3. Also, while Cigna continues to expect to close the sale of Cigna's Group Disability and Life business in the third quarter of 2020, Cigna's outlook assumes a full year of contributions from the Group Disability and Life business.

 

 

 
10 

 

The foregoing statements represent the Company’s current estimates of Cigna's 2020 consolidated adjusted revenues1,3 and adjusted income from operations2,3 on a per share basis as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the Cautionary Note Regarding Forward-Looking Statements included in this release. Management does not assume any obligation to update these estimates.

 

This quarterly earnings release and the Quarterly Financial Supplement are available on Cigna’s website in the Investor Relations section (https://www.cigna.com/aboutcigna/investors). Management will be hosting a conference call to review second quarter 2020 results and discuss full year 2020 outlook beginning today at 8:30 a.m. ET. A link to the conference call is available in the Investor Relations section of Cigna's website located at https://www.cigna.com/aboutcigna/investors/events/index.page.

 

The call-in numbers for the conference call are as follows:

 

Live Call

(888) 324-7575 (Domestic)

(210) 234-0013 (International)

Passcode: 7302020

 

Replay

(800) 839-1171 (Domestic)

(203) 369-3030 (International)

 

It is strongly suggested you dial in to the conference call by 8:15 a.m. ET.

 

 

About Cigna

 

Cigna Corporation (NYSE: CI) is a global health service company dedicated to improving the health, well-being and peace of mind of those we serve. Cigna delivers choice, predictability, affordability and access to quality care through integrated capabilities and connected, personalized solutions that advance whole person health. All products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Cigna Life Insurance Company of New York, Connecticut General Life Insurance Company, Express Scripts companies or their affiliates, and Life Insurance Company of North America. Such products and services include an integrated suite of health services, such as medical, dental, behavioral health, pharmacy, vision, supplemental benefits, and other related products including group life, accident and disability insurance.

 

Cigna maintains sales capability in over 30 countries and jurisdictions, and has more than 185 million customer relationships throughout the world. To learn more about Cigna®, including links to follow us on Facebook or Twitter, visit www.cigna.com.

 

 

Notes:

 

1.At the consolidated level, the measure “adjusted revenues” is not determined in accordance with accounting principles generally accepted in the United States (GAAP) and should not be viewed as a substitute for the most directly comparable GAAP measure, “total revenues.” Cigna defines adjusted revenues as total revenues excluding net realized investment results from equity method investments and special items. Special items are identified in Exhibit 1 of this earnings release. For periods prior to 2020, Cigna also excludes revenue contributions from transitioning pharmacy benefit management clients, Anthem Inc. and Coventry Health Care, Inc. (the “transitioning clients”). Cigna excludes these items from this measure because they are not indicative of past or future underlying performance of the business. See Exhibit 1 for a reconciliation of consolidated adjusted revenues to total revenues.

 

2.Adjusted income (loss) from operations is defined as shareholders’ net income (loss) excluding the following adjustments: net realized investment results, amortization of acquired intangible assets, and special items. For periods prior to 2020, Cigna also excludes earnings contributions from transitioning clients. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results.

 

 
11 

 

 

Adjusted income (loss) from operations is a measure of profitability used by Cigna’s management because it presents the underlying results of operations of Cigna’s businesses and permits analysis of trends in underlying revenue, expenses and shareholders’ net income. This consolidated measure is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’ net income. See Exhibit 1 for a reconciliation of consolidated adjusted income from operations to shareholders’ net income.

 

3.Certain adjusted metrics presented for 2019 exclude contributions from transitioning clients. As previously disclosed, beginning in 2020, Cigna no longer excludes contributions from transitioning clients from its adjusted metrics, as the transition for those clients was substantially complete as of December 31, 2019.

 

Management is not able to provide a reconciliation of adjusted income from operations to shareholders’ net income (loss) or adjusted revenues to total revenues on a forward-looking basis because it is unable to predict, without unreasonable effort, certain components thereof including (i) future net realized investment results (from equity method investments with respect to adjusted revenues) and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are beyond Cigna’s control. As such, any associated estimate and its impact on shareholders’ net income and total revenues could vary materially.

 

The Company’s outlook excludes the potential effects of any share repurchases or business combinations that may occur after the date of this earnings release. Additionally, the Company’s outlook assumes a full year of contributions from Cigna's Group Disability and Life business.

 

4.Operating ratios are defined as follows:
Medical care ratio represents medical costs as a percentage of premiums for all U.S. commercial risk products, including medical, pharmacy, dental, stop loss and behavioral products provided through guaranteed cost or experience-rated funding arrangements, as well as Medicare Advantage, Medicare Part D, Medicare Supplement, Medicaid, and individual on and off-exchange products, within Cigna’s Integrated Medical segment.
SG&A expense ratio represents enterprise selling, general and administrative expenses excluding special items and, prior to 2020, expenses from transitioning clients, as a percentage of adjusted revenue at a consolidated level.

 

5.Customer relationships are defined as follows:
Total medical customers includes individuals in Cigna’s Integrated Medical and International Markets segments who meet any one of the following criteria: are covered under a medical insurance policy, managed care arrangement, or service agreement issued by Cigna; have access to Cigna's provider network for covered services under their medical plan; or have medical claims and services that are administered by Cigna. 
U.S. Individual includes on-exchange Patient Protection and Affordable Care and Education Reconciliation Act (“ACA”) business, off-exchange ACA business and off-exchange non-ACA business.
Pharmacy customer relationships for periods prior to 2020 excludes transitioning clients.
International Markets supplemental policies exclude International Markets medical customers included in total medical customers.
Group Disability and Life covered lives are estimated.

 

6.Cigna owns a 50% non-controlling interest in its China joint venture. Cigna's 50% share of the joint venture’s earnings is reported in Fees and Other Revenues using the equity method of accounting under GAAP. As such, the adjusted revenues and policy counts for the International Markets segment do not include the China joint venture.

 

 
12 

 

 

7.Adjusted margin, pre-tax, is calculated by dividing adjusted income (loss) from operations, pre-tax by adjusted revenues for each segment.

 

Adjusted margin, after-tax, is calculated by dividing consolidated adjusted income (loss) from operations by consolidated adjusted revenues. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results.

 

8.For Health Services adjusted pharmacy scripts, non-specialty network scripts filled through 90-day programs and home delivery scripts are multiplied by three. All other network and specialty scripts are counted as one script.

 

9.Medical costs payable within the Integrated Medical segment are presented net of reinsurance and other recoverables. The gross medical costs payable balance was $2.96 billion as of June 30, 2020, $2.89 billion as of December 31, 2019, and $2.88 billion as of June 30, 2019.

 

10.Enhanced coverage for COVID-19 related services applies to customers in the United States who are covered under Cigna's employer/union sponsored insured group health plans, insured plans for globally mobile individuals, Medicare Advantage, Medicaid, and the Individual and Family insurance plans. Self-insured group health plans administered by Cigna have an opportunity to opt out of these benefits. Treatments covered include those covered under Medicare and other applicable state regulations.

 

11.The Cigna Foundation is a private foundation funded by contributions from Cigna Corporation and its subsidiaries.

 

 

 
13 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This press release, and oral statements made in connection with this release, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on Cigna's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning our projected consolidated adjusted income from operations outlook for 2020 on a per share basis; projected adjusted revenue outlook for 2020; future financial or operating performance, including our ability to deliver affordable, personalized and innovative solutions for our customers and clients, in light of the challenges presented by the COVID-19 pandemic; future growth, business strategy, strategic or operational initiatives, including our organizational efficiency plan; economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas; financing or capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; strategic transactions, including the merger (the “Merger”) with Express Scripts Holding Company and the sale of our U.S. Group Disability and Life business; our ongoing operational response to the COVID-19 pandemic; and other statements regarding Cigna's future beliefs, expectations, plans, intentions, financial condition or performance. You may identify forward-looking statements by the use of words such as “believe,” “expect,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “may,” “should,” “will” or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical and pharmacy costs and price effectively; our ability to adapt to changes or trends in an evolving and rapidly changing industry; our ability to effectively differentiate our products and services from those of our competitors and maintain or increase market share; our ability to develop and maintain good relationships with physicians, hospitals, other health care providers, producers, consultants, and pharmaceutical manufacturers; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing; the impact of modifications to our operations and processes; our ability to identify potential strategic transactions and realize the expected benefits (including anticipated synergies) of such transactions in full or within the anticipated time frame, including with respect to the Merger and the sale of our Group Disability and Life business, as well as our ability to integrate or separate operations, resources and systems; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions or guaranty fund assessments; uncertainties surrounding participation in government-sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems and those of our key suppliers or other third parties; the impact of our debt service obligations on the availability of funds for other business purposes; unfavorable industry, economic or political conditions, including foreign currency movements; acts of civil unrest, war, terrorism, natural disasters or pandemics; reinsurance credit risk; the scale and scope of the COVID-19 pandemic and its potential impact on our business, operating results, cash flows and financial condition, as well as on our employees, clients, customers, suppliers and partners and on the U.S. and global economies; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K, our Form 10-Q for the quarter ended March 31, 2020 and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of www.cigna.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Cigna undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

 

 
 

 

 

CIGNA CORPORATION EXHIBIT 1
COMPARATIVE SUMMARY OF FINANCIAL RESULTS (unaudited)
(Dollars in millions, except per share amounts)
          
  Three Months Ended  Six Months Ended  Three Months Ended
  June 30,  June 30,  March 31,
   2020  2019  2020  2019  2020
REVENUES               
Pharmacy revenues  $26,564   $26,288   $51,662   $51,467   $25,098 
Premiums   10,406    9,803    21,246    19,774    10,840 
Fees and other revenues   2,072    2,388    4,250    4,838    2,178 
Net investment income   223    340    576    686    353 
Total revenues   39,265    38,819    77,734    76,765    38,469 
Revenue contributions from transitioning clients   —      (4,450)   —      (8,939)   —   
Net realized investment results from certain equity method investments   (60)   6    (50)   (22)   10 
Special item related to contractual adjustment for a former client   —      —      (87)   —      (87)
Adjusted revenues (1)  $39,205   $34,375   $77,597   $67,804   $38,392 
                          
SHAREHOLDERS’ NET INCOME                         
                          
Shareholders' net income  $1,754   $1,408   $2,935   $2,776   $1,181 
After-tax adjustments to reconcile to adjusted income from operations                         
Net realized investment (gains) losses   (88)   (13)   (11)   (51)   77 
Amortization of acquired intangible assets   376    572    685    1,136    309 
Adjustment for transitioning clients   —      (506)   —      (1,010)   —   
Special Items                         
Debt extinguishment costs   11    —      151    —      140 
Integration and transaction-related costs   99    115    173    223    74 
Charge for organizational efficiency plan   —      —      24    —      24 
Charges associated with litigation matters   —      64    19    64    19 
Contractual adjustment for a former client   —      —      (66)   —      (66)
Adjusted income from operations  $2,152   $1,640   $3,910   $3,138   $1,758 
                          
Pre-tax adjusted income (loss) from operations by segment                         
Health Services  $1,249   $1,162   $2,331   $2,156   $1,082 
Integrated Medical   1,523    990    2,722    2,160    1,199 
International Markets   319    207    601    413    282 
Group Disability and Other   132    149    209    233    77 
Corporate   (400)   (453)   (805)   (943)   (405)
Consolidated pre-tax adjusted income from operations(2)   2,823    2,055    5,058    4,019    2,235 
Adjusted income tax expense   (671)   (415)   (1,148)   (881)   (477)
Consolidated after-tax adjusted income from operations(2)  $2,152   $1,640   $3,910   $3,138   $1,758 
                          
DILUTED EARNINGS PER SHARE                         
                          
Shareholders’ net income  $4.73   $3.70   $7.88   $7.26   $3.15 
After-tax adjustments to reconcile to adjusted income from operations                         
Net realized investment (gains) losses   (0.24)   (0.03)   (0.03)   (0.13)   0.21 
Amortization of acquired intangible assets   1.02    1.49    1.84    2.96    0.82 
Adjustment for transitioning clients   —      (1.33)   —      (2.64)   —   
Special Items                         
Debt extinguishment costs   0.03    —      0.41    —      0.38 
Integration and transaction-related costs   0.27    0.30    0.46    0.58    0.20 
Charge for organizational efficiency plan   —      —      0.06    —      0.06 
Charges associated with litigation matters   —      0.17    0.05    0.17    0.05 
Contractual adjustment for a former client   —      —      (0.18)   —      (0.18)
Adjusted income from operations(2)  $5.81   $4.30   $10.49   $8.20   $4.69 
Weighted average shares (in thousands)   370,697    380,969    372,668    382,496    374,639 
Common shares outstanding (in thousands)           368,258    377,883    369,317 
                          
SHAREHOLDERS' EQUITY at June 30,            $47,366   $43,815      
SHAREHOLDERS' EQUITY PER SHARE at June 30,            $128.62   $115.95      

 

(1) Adjusted revenues is defined as total revenues excluding the following adjustments: special items and Cigna's share of certain realized investment results of its joint ventures reported using the equity method. For periods prior to 2020, we also excluded revenue contributions from transitioning clients. These items are excluded because they are not indicative of past or future underlying performance of our businesses.

 

(2) Adjusted income (loss) from operations is defined as shareholders' net income (loss) excluding the following after-tax adjustments: realized investment results, amortization of acquired intangible assets and special items. For periods prior to 2020, we also excluded earnings contributions from transitioning clients.

GRAPHIC 3 tsgimage_001.jpg GRAPHIC begin 644 tsgimage_001.jpg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tsgimage_001.gif GRAPHIC begin 644 tsgimage_001.gif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ci-20200730.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 ci-20200730_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 ci-20200730_pre.xml XBRL PRESENTATION FILE XML 8 cigna8k_htm.xml IDEA: XBRL DOCUMENT 0001739940 2020-07-30 2020-07-30 iso4217:USD shares iso4217:USD shares 0001739940 false 8-K 2020-07-30 Cigna Corporation DE 001-38769 82-4991898 900 Cottage Grove Road Bloomfield CT 06002 (860) 226-6000 false false false false Common Stock, Par Value $0.01 CI NYSE false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover
Jul. 30, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 30, 2020
Entity File Number 001-38769
Entity Registrant Name Cigna Corporation
Entity Central Index Key 0001739940
Entity Tax Identification Number 82-4991898
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 900 Cottage Grove Road
Entity Address, City or Town Bloomfield
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06002
City Area Code (860)
Local Phone Number 226-6000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.01
Trading Symbol CI
Security Exchange Name NYSE
Entity Emerging Growth Company false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://cigna.com/role/Cover Cover Cover 1 false false All Reports Book All Reports cigna8k.htm ci-20200730.xsd ci-20200730_lab.xml ci-20200730_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cigna8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "cigna8k.htm" ] }, "labelLink": { "local": [ "ci-20200730_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "ci-20200730_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "ci-20200730.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "CI", "nsuri": "http://cigna.com/20200730", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "cigna8k.htm", "contextRef": "From2020-07-30to2020-07-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://cigna.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "cigna8k.htm", "contextRef": "From2020-07-30to2020-07-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 16 0000950159-20-000161-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950159-20-000161-xbrl.zip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end